You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 30, 2025

Drug Sales Trends for ARIPIPRAZOLE


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for ARIPIPRAZOLE (2021)

Revenues by Pharmacy Type

23.4%8.4%68.2%020000000400000006000000080000000100000000120000000140000000160000000MAIL-ORDERINSIDE ANOTHER STORE[disabled in preview]
Pharmacy Type Revenues
MAIL-ORDER $56,789,276
INSIDE ANOTHER STORE $20,254,368
[disabled in preview] $165,312,797
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

10.0%22.1%67.9%05000001000000150000020000002500000300000035000004000000MAIL-ORDERINSIDE ANOTHER STORE[disabled in preview]
Pharmacy Type Units
MAIL-ORDER 589,657
INSIDE ANOTHER STORE 1,305,924
[disabled in preview] 4,003,807
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

14.0%16.6%69.4%0400000006000000080000000100000000120000000140000000160000000180000000MEDICAIDMEDICARE[disabled in preview]
Payment Method Revenues
MEDICAID $33,937,434
MEDICARE $40,304,186
[disabled in preview] $168,114,822
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for ARIPIPRAZOLE
Drug Units Sold Trends for ARIPIPRAZOLE

Annual Sales Revenues and Units Sold for ARIPIPRAZOLE

These sales figures are drawn from a US national survey of drug expenditures
Drug NameRevenues (USD)UnitsYear
ARIPIPRAZOLE ⤷  Try for Free ⤷  Try for Free 2021
ARIPIPRAZOLE ⤷  Try for Free ⤷  Try for Free 2020
ARIPIPRAZOLE ⤷  Try for Free ⤷  Try for Free 2019
ARIPIPRAZOLE ⤷  Try for Free ⤷  Try for Free 2018
ARIPIPRAZOLE ⤷  Try for Free ⤷  Try for Free 2017
ARIPIPRAZOLE ⤷  Try for Free ⤷  Try for Free 2016
>Drug Name>Revenues (USD)>Units>Year
Showing 1 to 6 of 6 entries

Aripiprazole Market Analysis and Sales Projections

Introduction to Aripiprazole

Aripiprazole, a second-generation antipsychotic medication, is widely used for treating various mental health conditions, including schizophrenia, bipolar disorder, major depressive disorder, Tourette syndrome, and irritability associated with autism. Its unique mechanism of action, involving partial agonism at serotonin 5-HT1A and dopamine D2 receptors, as well as antagonism at serotonin 5-HT2A receptors, makes it a valuable therapeutic option.

Current Market Size and Growth Projections

The global Aripiprazole market has shown significant growth in recent years. As of 2023, the market size was valued at different figures depending on the scope of the report:

  • Global Aripiprazole Drug Market: Valued at US$ 121 million in 2023 and is expected to reach US$ 167.1 million by 2030, growing at a CAGR of 5.1% during the forecast period 2024-2030[1].
  • Broader Aripiprazole Market: Valued at USD 22.7 billion in 2023 and projected to reach USD 33.5 billion by 2030, growing at a CAGR of 6.1% during the forecast period 2024-2030[4].

Key Drivers of Market Growth

Several factors are driving the growth of the Aripiprazole market:

  • Rising Incidence of Mental Health Issues: The increasing prevalence of mental health disorders such as schizophrenia, bipolar disorder, and major depressive disorder is a significant driver. As awareness and diagnosis rates improve, the demand for effective therapies like Aripiprazole is on the rise[4].
  • Advancements in Drug Delivery and Formulation: Improvements in drug delivery methods and formulation processes have enhanced the efficacy and tolerability of Aripiprazole, making it more appealing to patients and healthcare providers[4].
  • Strategic Alliances and Joint Ventures: Pharmaceutical companies are engaging in strategic alliances and joint ventures to develop innovative formulations and expand their customer base, further boosting market growth[4].

Impact of Patent Expiry and Generic Competition

A critical factor influencing the Aripiprazole market is the impending loss of market exclusivity for Otsuka's Abilify Maintena (aripiprazole) in both Europe and the US in October 2024. This event is expected to lead to a significant decline in sales for Otsuka:

  • Sales Decline: A 12% decline in Otsuka’s sales is anticipated from 2024 to 2025, with a projected negative CAGR of 21% from 2024 to 2029. Sales are expected to plummet from $1.5 billion in 2024 to $459 million by the end of 2029[2].
  • Generic Competition: The introduction of generic versions of Aripiprazole will increase competition and reduce prices, making the drug more accessible to a larger patient population but negatively impacting Otsuka’s revenue[2].

Market Segmentation

The Aripiprazole market is segmented in various ways to understand its dynamics better:

  • By Type: The market includes tablets, orally disintegrating tablets, and oral solutions[1].
  • By Application: The drug is used for adult and pediatric patients[1].
  • By Distribution Channel: Sales occur through hospital pharmacies, retail pharmacies, and online pharmacies[5].
  • By Patient Age Group: The market is segmented into pediatric, adult, and geriatric patient groups[5].
  • By Region: The market is analyzed across North America, Europe, South America, Asia Pacific, and the Middle East and Africa[5].

Key Players

The Aripiprazole market is dominated by several key players:

  • Otsuka Pharmaceutical: The developer of Abilify Maintena, a blockbuster drug[2].
  • Teva, APOTEX, Barr Laboratories, Sun Pharmaceutical, Alembic Pharmaceuticals, Orchid Pharma, Amneal, Aurobindo Pharma, Lannett, Solco Healthcare, Delphis Pharma: These companies are significant players in the global Aripiprazole market[1].
  • Akhil Healthcare, Cambrex, Polpharma, Cadila, Bal Pharma, Mapi Pharma, Tiefenbacher API + Ingredients, SMS Pharmaceuticals, Jiuzhou Pharmaceutical: Other notable companies involved in the broader Aripiprazole market[4].

Market Trends and Future Outlook

The future of the Aripiprazole market is shaped by several trends:

  • Increased Focus on Mental Health: Advocacy and destigmatization initiatives are expected to continue driving the uptake of Aripiprazole and other mental health treatments[4].
  • Innovative Formulations: Ongoing research and development in drug delivery and formulation are likely to enhance the market appeal of Aripiprazole[4].
  • Generic Competition: The entry of generic versions will make the drug more affordable and accessible, potentially expanding the market size despite the decline in sales for branded versions[2].

Key Takeaways

  • The global Aripiprazole market is expected to grow, driven by increasing mental health awareness and advancements in drug formulations.
  • The loss of market exclusivity for Otsuka’s Abilify Maintena will lead to a decline in sales for the company but increase accessibility for patients.
  • Key players are focusing on strategic alliances and innovative formulations to maintain market share.
  • The market is segmented by type, application, distribution channel, patient age group, and region.

FAQs

Q: What is the current market size of the Aripiprazole drug market? A: The global Aripiprazole drug market was valued at US$ 121 million in 2023[1].

Q: What is the projected growth rate of the Aripiprazole market from 2024 to 2030? A: The market is expected to grow at a CAGR of 5.1% from 2024 to 2030[1].

Q: How will the loss of market exclusivity for Abilify Maintena impact Otsuka’s sales? A: Otsuka’s sales are expected to decline by 12% from 2024 to 2025, with a negative CAGR of 21% from 2024 to 2029[2].

Q: What are the main conditions treated with Aripiprazole? A: Aripiprazole is used to treat schizophrenia, bipolar disorder, major depressive disorder, Tourette syndrome, and irritability associated with autism[4].

Q: Who are the key players in the Aripiprazole market? A: Key players include Otsuka Pharmaceutical, Teva, APOTEX, Barr Laboratories, Sun Pharmaceutical, and several others[1][4].

Sources

  1. Global Aripiprazole Drug Market Research Report 2024 - Valuates Reports
  2. Otsuka's Abilify Maintena: dual drug expiry signals sales decline - Pharmaceutical Technology
  3. Aripiprazole Drug Market Report 2024 (Global Edition) - Cognitive Market Research
  4. Aripiprazole Market Size, Share, Scope, Trends And Forecast 2030 - Verified Market Reports
  5. Aripiprazole Market Size, Growth, Trends, Report 2032 - Market Research Future

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.